Results For "0"

Certara Launches Early Development Solution to Reduce Failure Rates in Early-Stage Drug Development Blog Post

New solution offers early-stage developers a dedicated team of experts with combined experience in end-to-end drug development to optimize delivery timelines, derisk programs, and improve outcomes. RADNOR, PA – SEPTEMBER…

Certara & Ichnos Glenmark Innovation Collaboration Optimizes Dosing Strategy for Potential First-In-Class Cancer Drug Blog Post

Preclinical research on the trispecific antibody, ISB 2001, published in Nature Cancer leveraged virtual trials to select a higher starting dose that would lower costs and reduce cycle times RADNOR, PA…

ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells Blog Post

要旨 単一の腫瘍関連抗原を標的とする免疫療法での最近の進歩にもかかわらず、多発性骨髄腫の患者はやがて再発します。ISB 2001 is a CD3+ T cell engager (TCE) co-targeting BCMA and CD38 designed…

A Next Generation Mathematical Model for the in vitro to Clinical Translation of T-cell Engagers Blog Post

Abstract T-cell engager (TCE) molecules activate the immune system and direct it to kill tumor cells. The key mechanism of action of TCEs is to crosslink CD3 on T cells…

オンデマンド [ISoP ウェビナー] – モデルを活かした医薬品開発（MIDD）における生理学的薬物動態（PBPK）の応用 – 規制当局の現状の受け入れ状況をご存知ですか？ Blog Post

モデルを活かした医薬品開発（MIDD）は、医薬品開発プロセスおよび規制当局による審査において重要な要素です。It is frequently utilized as part of a Clinical Pharmacology strategy to inform…

A Best Practice Guide to Managing Non-CRF Data Blog Post

Download PDF

Inferring Target Occupancy for Pembrolizumab Blog Post

Pembrolizumab (Pembro), an anti-PD-1 antibody, has been approved for several cancer indications at 200 mg or 2 mg/kg IV every 3 weeks (Q3W). Understanding the percent target receptor occupancy (RO)...

Dynamic Target-Mediated Drug Disposition (TMDD) Blog Post

Abstract Methods: We have developed a novel pharmacokinetic model, termed dynamic TMDD, to mechanistically describe the phenomenon of drug induced changes in target expression and resultant TMDD. The model is based…

Semi-mechanistic Model of ATG-101, a PD-L1/4-1BB Bispecific Antibody, for Treatment of Solid Tumors Blog Post

Abstract Trimer formation is key to the pharmacology of the bispecific ATG-101 but is difficult to measure. ATG-101 is a bispecific antibody that crosslinks tumor-expressed PD-L1 to T-cell-expressed 4-1BB, thereby…

Industry Sense – Drug Repurposing Unlocking New Therapeutic Possibilities Blog Post

Panelists: Adekemi Taylor, PhD, VP, Quantitive Science Services at CertaraJoab Williamson, Director of Clinical Operations, Faron Pharmaceuticals Summary: LI Pharma Focus America – Issue 04 (2024年8月31日) features a…